Literature DB >> 22020357

A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.

Juliana Belo Diniz1, Roseli Gedanke Shavitt, Victor Fossaluza, Lorrin Koran, Carlos Alberto de Bragança Pereira, Euripedes Constantino Miguel.   

Abstract

Obsessive-compulsive disorder patients who do not improve sufficiently after treatment with a selective serotonin reuptake inhibitor might improve further if other drugs were added to the treatment regimen. The authors present a double-blind, placebo-controlled trial comparing the efficacy of adding quetiapine or clomipramine to a treatment regimen consisting of fluoxetine. Between May 2007 and March 2010, a total of 54 patients with a primary diagnosis of obsessive-compulsive disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and a current Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of at least 16, the score having dropped by less than 35% after fluoxetine monotherapy, were allocated to 1 of 3 arms (n = 18 per arm): quetiapine + fluoxetine (≤200 and ≤40 mg/d, respectively), clomipramine + fluoxetine (≤75 and ≤40 mg/d, respectively), or placebo + fluoxetine (≤80 mg/d of fluoxetine). Follow-up was 12 weeks. The Y-BOCS scores were the main outcome measure. No severe adverse events occurred during the trial, and 40 patients (74%) completed the 12-week protocol. The Y-BOCS scores (mean [SD]) were significantly better in the placebo + fluoxetine and clomipramine + fluoxetine groups than in the quetiapine + fluoxetine group (final: 18 [7] and 18 [7], respectively, vs 25 [6], P < 0.001) (reduction from baseline: -6.7 [confidence interval {CI}, -9.6 to -3.8; and -6.5 [CI, -9.0 to -3.9], respectively, vs -0.1 [CI, -2.9 to 2.7], P < 0.001; number needed to treat = 2.4). The clomipramine-fluoxetine combination is a safe and effective treatment for fluoxetine nonresponders, especially those who cannot tolerate high doses of fluoxetine. However, the period of monotherapy with the maximum dose of fluoxetine should be extended before a combination treatment strategy is applied.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020357     DOI: 10.1097/JCP.0b013e3182367aee

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  12 in total

1.  Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.

Authors:  Joseph F McGuire; Adam B Lewin; Daniel A Geller; Ashley Brown; Kesley Ramsey; Jane Mutch; Andrew Mittelman; Jamie Micco; Cary Jordan; Sabine Wilhelm; Tanya K Murphy; Brent J Small; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2012-08

Review 2.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

Review 3.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

4.  D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis.

Authors:  Deborah Ducasse; Laurent Boyer; Pierre Michel; Anderson Loundou; Alexandra Macgregor; Jean-Arthur Micoulaud-Franchi; Philippe Courtet; Mocrane Abbar; Marion Leboyer; Guillaume Fond
Journal:  Psychopharmacology (Berl)       Date:  2014-03-06       Impact factor: 4.530

5.  Efficacy and safety of transcranial direct current stimulation as an add-on treatment for obsessive-compulsive disorder: a randomized, sham-controlled trial.

Authors:  Renata de Melo Felipe da Silva; Andre R Brunoni; Stephan Goerigk; Marcelo Camargo Batistuzzo; Daniel Lucas da Conceição Costa; Juliana Belo Diniz; Frank Padberg; Giordano D'Urso; Eurípedes Constantino Miguel; Roseli Gedanke Shavitt
Journal:  Neuropsychopharmacology       Date:  2021-01-15       Impact factor: 7.853

6.  Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.

Authors:  Markus Dold; Martin Aigner; Rupert Lanzenberger; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2015-05-04       Impact factor: 5.176

7.  Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).

Authors:  Márcio G Soeiro-DE-Souza; Vasco Videira Dias; Giovanni Missio; Vicent Balanzá-Martinez; Leandro Valiengo; André F Carvalho; Ricardo Alberto Moreno
Journal:  Exp Ther Med       Date:  2015-01-23       Impact factor: 2.447

Review 8.  Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.

Authors:  David Veale; Sarah Miles; Nicola Smallcombe; Haben Ghezai; Ben Goldacre; John Hodsoll
Journal:  BMC Psychiatry       Date:  2014-11-29       Impact factor: 3.630

Review 9.  Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.

Authors:  Dongmi Kim; Nicole L Ryba; Julie Kalabalik; Ligia Westrich
Journal:  Drugs R D       Date:  2018-09

10.  Does Curcumin or Pindolol Potentiate Fluoxetine's Antidepressant Effect by a Pharmacokinetic or Pharmacodynamic Interaction?

Authors:  H A S Murad; M I Suliaman; H Abdallah; May Abdulsattar
Journal:  Indian J Pharm Sci       Date:  2014-05       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.